Q-omics provides the consensus-scored MARK4 profile across patient tissues and cancer cell-line models. MARK4 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MARK4 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, MARK4 RNA expression shows 19,615 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where MARK4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARK4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARK4 survival associations across molecular data types. MARK4 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARK4 RNA expression–survival associations across cancer types. High MARK4 expression shows unfavorable associations in HNSC, ACC, UCEC and UCS, but favorable associations in SCLC and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MARK4 RNA expression.
This table summarizes MARK4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MARK4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARK4 shows higher tumor expression in HNSC, KIRC, KIRP, COAD, LIHC and LUSC. The HNSC box plot shows higher MARK4 RNA expression in tumor versus normal tissue (log2 FC = +0.887, t-test p < 0.001).
This table shows molecular features associated with MARK4 in patient tissues and cancer cell lines. In patient samples, MARK4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MARK4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
